1. miR-146a and miR-146b are upregulated during premalignancy in the thymus of T cellspecific PTEN-deficient mice.
Introduction
Malignant cancer is typically preceded by the development of premalignant lesions.
However, not all premalignant lesions progress to malignancy. 1 Premalignant cells arise in large part due to genetic alterations that promote excessive growth and proliferation. 2 Characterizing changes in gene expression that occur in premalignant lesions could aid in correlating cellular responses to transformation with the risk of disease progression. 2 Furthermore, it could lead to identification of factors mediating the anti-tumor response that might inspire the design of more effective targeted therapeutics. While the biological heterogeneity of human premalignant lesions makes them difficult to study, premalignant lesions have been identified in many genetic mouse models of human cancer. The genetic homogeneity of mice can lead to more synchronous development of homogenous lesions, greatly facilitating the study of premalignancy. 3 Phosphatase and Tensin Homolog (PTEN) is one of the most frequently inactivated tumor suppressors in human cancer. 4 PTEN dephosphorylates 3-phosphoinositide products of PI3 kinase (PI3K), thereby negatively regulating PI3K-Akt signaling, which promotes cell growth and proliferation. 5, 6 Pten is inactivated in many cancers by loss of heterozygosity, mutation or deletion, with high incidence in glioma, breast cancer, melanoma, prostate cancer, leukemia and lymphoma. 4 In T cell acute lymphoblastic leukemia/lymphoma (T-ALL), Pten mutations have been identified in up to 27% of patients analyzed. 7 Deletions are found in greater than 8% of patients and have been associated with early treatment failure. 7, 8 Consequential hyperactivation of the PI3K-Akt pathway is also commonly observed. 9 In cases where Pten is not altered at the genomic level, PTEN expression is still frequently downregulated. 8 T cell-specific deletion of PTEN in mice induces premalignancy in CD4 + CD8 + (Double Positive, DP) thymocytes, which progresses to CD4 + T cell lymphoma in the lymph nodes and spleen. [10] [11] [12] Interestingly, premalignancy occurs only in 6 weeks or older animals. In younger mice, T cell development in T-cell specific PTEN deficient mice (tPTEN -/-) is completely normal For personal use only. on November 16, 2017 . by guest www.bloodjournal.org From with no signs of malignancy. 10 Premalignant thymocytes harbor T cell receptor (TCR) signalingdependent TCRα/c-myc chromosomal translocations that promote c-myc upregulation, critical for promoting transformation of these cells. 11 Premalignancy is also characterized by increased activation of the PI3K-Akt signaling pathway and induction of a senescence program. 10 However, since DP thymocytes do not proliferate to any significant degree, it is unlikely that senescence acts as a barrier to transformation in this model. 10 Thus, we sought to identify other factors that stave off transformation in premalignant PTEN-deficient DP cells.
Through microRNA (miRNA) expression analyses, we have identified miRNAs miR-146a and miR-146b as being significantly upregulated in premalignant DP cells of tPTEN -/mice.
Strikingly, T cell-specific expression of mir-146a and mir-146b transgenes significantly delayed tPTEN -/lymphomagenesis, supporting their expression as a barrier to transformation. Tumor suppression was mediated by miR-146 attenuation of TCR signaling through repression of its target Traf6, an important activator of NF-κB. Our results not only support the potential therapeutic applications of these tumor suppressive miRNAs, but also suggest a general strategy for the identification of miRNAs that inhibit transformation in other cancer models.
Materials and Methods

Mice
Characterization of the Lck-Cre Pten fl/fl (tPTEN -/-) mice has previously been reported. 10, 13 Analyses were performed on a mixed 129Sv/J x CBA x C57/BL6 background or a C57BL/6 background (backcrossed more than 10 generations). All the animal-related procedures have been approved by the UC Berkeley Animal Care and Use Committee.
The miRNA transgenic mouse constructs were generated by cloning PCR-amplified pre-miRNA sequences with approximately 450bp of flanking sequence into the pTG4 construct. 14, 15 The primer sequences used were: miR-146a-forward ATCGATCGCTCGAGTCTGGCTAGCCTGG, miR-146a-reverse 
Results
Upregulation of several miRNAs correlates with premalignancy in PTEN-deficient DP thymocytes
To identify miRNAs that might act to inhibit transformation of PTEN-deficient DP thymocytes, we performed a miRNA microarray on sorted DP cells from three 9-week-old tPTEN -/mice and three littermate controls ( Figure 1A ). 9-week-old tumor-free tPTEN -/mice were selected based on our prior correlation of premalignancy with this age. 10 We observed that 43 of 599 miRNAs were differentially expressed in the tPTEN -/samples. qRT-PCR validation of these results indicated that several miRNAs were upregulated specifically in 9-week tPTEN -/-DP and sometimes CD4 SP thymocytes, but not in the corresponding mature T cells ( Figure 1B, supplemental Figure 1A ). Interestingly, upregulation was not detected in DP thymocytes from 5week-old mice, where premalignancy has not yet occurred, indicating that these miRNAs are specifically induced during the premalignant period. We identified miR-146a as one of the most highly upregulated miRNAs in 9-week tPTEN -/-DP thymocytes. Expression of highly homologous family member miR-146b was also increased. Though encoded on different chromosomes, miR-146a and miR-146b have identical seed sequences and differ by only 2 nucleotides at the 3' end, and therefore are predicted to have similar mRNA targets. Also highly upregulated in 9-week-old DP thymocytes were the miRNAs of the miR-183/96/182 cluster, miR-151-5p and miR-342-3p (supplemental Figure 1A) . We hypothesized that one or more of these miRNAs might be upregulated to inhibit malignant transformation of PTEN-deficient DP thymocytes.
For personal use only. on November 16, 2017. by guest www.bloodjournal.org From Analysis of a larger cohort of 9-week-old tPTEN -/mice, however, revealed that these miRNAs are not always as highly upregulated at this age, consistent with the more modest phenotype observed for sample tPTEN -/-2 in the miRNA microarray. Analysis of c-myc expression in these mice uncovered a striking correlation between miRNA upregulation and high c-myc expression ( Figure 1C ). 11 c-myc upregulation was only observed in DP thymocytes and not in more mature thymocytes or T cells, paralleling the miRNA expression pattern we observed ( Figure 1D ). However, it is unlikely that c-myc drives expression of these miRNAs as prior analysis of c-myc regulation of global miRNA expression by others found that c-myc activation does not increase their expression. 16, 17 In 12-week-old tPTEN -/mice harboring CD4 + T cell lymphomas, miR-146a and -146b expression in sorted CD4 + mature T cells was often downregulated ( Figure 1E ). This expression pattern is consistent with that observed for tumor suppressive miRNAs, such as miR-34a or let-7, as their downregulation is advantageous to the tumor. 18 In contrast, the miR-183/96/182 cluster was further upregulated in tumor cells (data not shown).
Generation of T cell-specific miRNA transgenic mice
To test whether upregulation of miR-146a or miR-146b might act to inhibit malignant transformation of tPTEN -/-DP thymocytes, we generated T cell-specific mir-146a and mir-146b transgenic mice. The miRNA transgenes were expressed under the control of the CD4 regulatory elements as previously described. 14, 15 The transgenic mice were generated on the C57BL/6 background and two 146a founder lines (a1 and a8) and one 146b founder line were used for analysis.
By RNase protection assay, we observed that miR-146a is normally expressed at low levels in thymocytes. In the mir-146a transgenic mice, miR-146a expression is increased to a level similar to that of miR-16, a miRNA that is abundant in thymocytes (Figure 2A ). 19 This increase in miR-146a expression is lymphoid tissue-specific, as no upregulation was observed For personal use only. on November 16, 2017. by guest www.bloodjournal.org From in the liver or kidneys (supplemental Figure 2A ). The highest levels of mir-146a transgene expression were detected in DP thymocytes, followed by CD4 SP thymocytes and CD4 + mature T cells ( Figure 2B ). Some mir-146a transgene expression was also observed in CD4 -CD8 -(Double Negative, DN) thymocytes and CD8 + mature T cells. Importantly, the level of miR-146 transgene expression in DP thymocytes was similar between all of the transgenic lines analyzed ( Figure 2C ).
mir-146a and mir-146b transgene expression inhibits tPTEN -/lymphomagenesis
To determine whether miR-146a and miR-146b over-expression can inhibit PTENdeficient lymphomagenesis, the mir-146a and mir-146b transgenic lines were crossed to the tPTEN -/mice. In preparation for the cross, the tPTEN -/mice were backcrossed to C57BL/6 to To elucidate the mechanism by which miR-146a and miR-146b delay tumorigenesis, we first evaluated whether over-expression of the miRNAs alters T cell development. T cell development occurs normally in the mir-146a transgenic lines, with no significant differences in T cell proportions in the thymus or lymph nodes on wild-type (WT) or tPTEN -/backgrounds (supplemental Figure 2B ). mir-146b transgenic mice had normal thymic cell proportions, however CD4 T cell proportions were consistently reduced, with a 2-fold decrease in CD4 T cell number in the lymph nodes regardless of PTEN status ( Figure 2F ). The mir-146b transgenic CD4 T cells had a modest but consistent reduction in surface expression of CD62L, which is normally upregulated upon thymic egress to mediate homing to the lymph nodes and spleen ( Figure 2G ). Reduced T cell homing to the lymph nodes might contribute to the lower 146b CD4 T cell numbers. In contrast, 146a8 CD4 T cells expressed normal levels of CD62L (supplemental Figure 2C) . 146b CD4 T cell maturation was otherwise generally unaffected, with appropriate upregulation of Qa-2 and downregulation of HSA. CD62L levels in SP thymocytes were also largely normal (supplemental Figures 2B/2C ). Thus, T cell development appears largely unaltered by mir-146a and mir-146b transgene expression, with the exception of a moderate reduction in CD4 T cells numbers in the 146b transgenic mice.
miR-146 over-expression delays c-myc upregulation associated with premalignancy
To evaluate whether miR-146 over-expression delays tPTEN -/tumor formation, we first sought to characterize the premalignant state of tPTEN -/mice on the C57/BL6 background.
Consistent with the increased survival of C57/BL6 tPTEN -/mice, the appearance of premalignant markers is delayed compared to tPTEN -/mice on a mixed background. 10 Beginning around 11 weeks, blasting, characterized by increased forward and side scatters, is apparent in the thymus, but not the lymph nodes of tPTEN -/mice (Early Premalignant, Figure   3A ). A slight increase in phosphorylated-Akt (P-Akt) is also evident in CD4 SP thymocytes ( Figure 3B ). Progression from early to late premalignancy is signified by more pronounced blasting and high levels of P-Akt in DP and CD4 SP thymocytes, but not mature T cells ( Figure   3B ). Paralleling P-Akt levels, Ki67 expression is also increased in DP and CD4 SP thymocytes during late premalignancy ( Figure 3B ). Importantly, DP thymocytes normally express high levels of Ki67, even though they don't proliferate. 10, 14 Increased c-myc expression corresponds with late premalignancy, as increased c-myc mRNA levels are found only in thymocytes expressing high levels of both phosphorylated Akt and Ki67 ( Figure 3C ). Consistent with this observation, increased c-myc protein levels were observed in the thymus, but not in the lymph node T cells of 12-week-old late premalignant mice ( Figure 4A ). However, in 13.5-week-old tPTEN -/mice that have developed tumors, c-myc upregulation was apparent in both compartments.
Interestingly, no c-myc upregulation was observed in two 13.5-week-old littermate 146a8/tPTEN -/mice in either compartment ( Figure 4A ). We also did not observe c-myc upregulation at the transcript level in thymocytes of [14] [15] week tumor-free 146a1/tPTEN -/and 146b/tPTEN -/mice compared to littermate tPTEN -/controls that had acquired tumors by this age ( Figure 4B ). These data suggest that miR-146 over-expression might act to delay c-myc upregulation associated with premalignancy. To more comprehensively assess the impact of miR-146 over-expression on premalignancy, we assessed blasting, phosphorylated-Akt levels, Ki67 expression and thymic c-myc mRNA expression in a large cohort of 13.5 to 15-week-old littermate or age-matched tPTEN -/and 146/tPTEN -/mice. These mice were then classified as early premalignant, late premalignant or malignant based on the criteria outlined above. A large majority of the 146/tPTEN -/mice were found to be in early premalignancy, compared to tPTEN -/mice, which were primarily in late premalignancy or had already developed tumors ( Figure 4C ).
These data suggest that miR-146 over-expression acts to prolong the survival of tPTEN -/mice by delaying progression to malignancy or by inhibiting expansion of premalignant thymocytes. 
miR-146 negatively regulates TCR signaling in thymocytes
TCRα/c-myc translocations in PTEN-deficient thymocytes were previously demonstrated to be TCR signaling-dependent. 11 In mature T cells, miR-146a expression is induced by TCR stimulation and miR-146a then acts in a negative feedback loop to repress TCR signaling. 20, 21 We hypothesized that miR-146a and miR-146b might similarly be induced by TCR signaling in DP thymocytes and act in a negative feedback loop to inhibit TCR signals necessary for TCRα/c-myc translocations/c-myc upregulation. Indeed, we found that miR-146a and miR-146b were significantly upregulated in TCR-stimulated DP thymocytes from both WT and tPTEN -/-5-week-old mice ( Figure 5A , supplemental Figure 3 ). However, miR-146b was upregulated less than miR-146a, consistent with less induction of miR-146b compared to miR-146a in premalignant tPTEN -/-DP thymocytes. Since strong amplification of Akt signaling is observed in late premalignant thymocytes, we tested whether Akt signaling downstream of the TCR might be responsible for miR-146a and miR-146b upregulation. Inhibition of Akt signaling with PI3K inhibitor LY294002 almost completely abrogated miR-146a and miR-146b induction in TCRstimulated DP thymocytes ( Figure 5A, supplemental Figure 3 ). Thus, Akt signaling downstream of the TCR is likely responsible for miR-146a and miR-146b upregulation during premalignancy in tPTEN -/mice.
In retrovirally transduced mature T cells, miR-146a has been shown to attenuate TCR signaling by targeting Traf6, a ubiquitin ligase that plays a key role in activating NF-κB. 20, 22 We hypothesized that miR-146 might act similarly in thymocytes to dampen the TCR signals that drive TCRα/c-myc translocations. Indeed, we found that Traf6 expression is reduced in tPTEN -/thymocytes from premalignant and tumor-bearing mice ( Figure 5B ). Additionally, in both mir-146a and mir-146b transgenic mice, we observed a significant reduction in Traf6 expression at both the transcript and protein levels on WT and tPTEN -/backgrounds ( Figure 5C , supplemental Figure 4 ). The reduction in Traf6 expression was not due to global downregulation of miR-146 target genes as the expression of Stat1, a reported target of miR-146a in T cells whose 3' UTR has only partial homology to the miR-146a seed sequence 23 , was not downregulated in either thymocytes or mature T cells of the mir-146a transgenic mice ( Figure   5D ). We next tested whether Traf6 downregulation by miR-146 results in decreased NF-κB activation downstream of TCR signals by measuring degradation of the NF-κB inhibitor IκBα.
Upon PMA and Ionomycin stimulation, we observed that IκBα degradation was significantly attenuated in mir-146 transgenic thymocytes ( Figure 5E Additionally, diminished endogenous c-myc levels due to NF-κB inhibition might increase the threshold for survival and proliferation of transforming thymocytes.
Reduced proliferative capacity of mir-146b transgenic CD4 T cells
As shown above, T cell development in mir-146a and mir-146b transgenic mice is largely normal with exception of reduced CD4 T cells in the mir-146b transgenic mice. Since TCR signals are important for survival of mature T cells 24 , we wondered if miR-146b attenuation of TCR signaling might contribute to the lower T cell numbers. Strikingly, we found that mir-146b transgenic CD4 T cells were significantly impaired in their ability to expand in response to TCR stimulation ( Figure 6A ). This effect was amplified on the tPTEN -/background. Co-cultured CD8 T cell expansion was normal, likely due to the absence of transgenic mir-146b expression ( Figure 6A) . Surprisingly, mir-146a transgenic CD4 T cell expansion was completely normal ( Figure 6B ). This observation is in agreement with our finding that mir-146a transgenic mice have normal T cell proportions.
A defect in TCR-mediated T cell expansion could be caused by insufficient activation through the TCR. However, mir-146b transgenic CD4 T cells upregulated activation markers CD69 and CD25 normally (supplemental Figure 5 ). Alternatively, this defect could be caused by increased apoptosis. In response to TCR stimulation, we observed a modest increase in apoptosis of 146b CD4 T cells ( Figure 6C ). However, we were unable to rescue the expansion defect with the pan-caspase inhibitor zVAD-FMK (supplemental Figure 6 ), suggesting increased cell death is not the critical defect in 146b T cells. Interestingly, we found that 146b CD4 T cells have a pronounced defect in proliferation, with a reduced ability to dilute CFSE over time ( Figure 6D ). Cell cycle analysis of BrdU-pulsed T cells revealed that this defect was due to inhibition of the G 0 /G 1 to S-phase cell cycle transition (24hr and 48hr, Figure 7A ). In mature T For personal use only. on November 16, 2017. by guest www.bloodjournal.org From cells, NF-κB activation is important for inducing expression of genes that drive the G 0 /G 1 to Sphase transition, most importantly c-myc. 25 Interestingly, Traf6 expression was significantly decreased in 146b/tPTEN -/and to some extent 146a/tPTEN -/-CD4 T cells ( Figure 7B ).
Consistent with a corresponding reduction in NF-κB activity, we found that c-myc levels were significantly reduced in 146b CD4 T cells and to a lesser extent in 146a CD4 T cells ( Figure 7C , supplemental Figure 7) . Furthermore, increased expression of the cell cycle inhibitor p27 in naïve 146b CD4 T cells and somewhat in 146a CD4 T cells was observed. Thus, decreased cmyc induction and high p27 levels likely cooperate to inhibit 146b T cell proliferation.
Discussion
Inactivation of the tumor suppressor PTEN renders cells vulnerable to malignant
transformation, however additional oncogene activation is frequently necessary to drive forward the transformation process. 4 In human T-ALL, PTEN loss is frequently coupled with increased expression of the c-myc oncogene. 26 Activating mutations of NOTCH1, which are found in 50%
of T-ALL patients, also drive concurrent c-myc amplification and PTEN suppression. 8, 27 In mice, c-myc upregulation is observed in both T cell-specific and hematopoietic-specific PTENdeficient mice 11, 28, 29 , largely driven by the presence of TCRα/c-myc chromosomal translocations 11, 30 . In one model, concurrent deletion of c-myc completely abrogated leukemia/lymphoma development. 28 Thus, in both humans and mice, activation of c-myc plays a key role in promoting development of PTEN-deficient T cell malignancies. Here, through analysis of premalignant lesions in tPTEN -/mice, we have identified two miRNAs that act to delay this crucial c-myc induction and inhibit development of lymphomas.
Through analysis of mir-146a and mir-146b T cell-specific transgenic mice, we found that both miRNAs act to suppress TCR signals in thymocytes. Intact TCR signaling is a prerequisite for TCRα/c-myc translocations in PTEN-deficient premalignant thymocytes. 11 By dampening TCR signals, these miRNAs might act to decrease the incidence of translocations, The perfect seed sequence homology between miR-146a and miR-146b predicts that these two miRNAs should have the same mRNA targets and function redundantly. 18 Consistent with this, our studies indicate that both miRNAs act similarly to repress Traf6, thereby negatively regulating NF-κB signaling and c-myc induction. However, the magnitude of this phenotype was somewhat attenuated in mir-146a versus mir-146b transgenic mice. The impact of this was most apparent in mature T cells, where transgenic expression of mir-146b, but not mir-146a, resulted in decreased CD4 T cell numbers and impaired TCR-mediated proliferation. However, while this T cell phenotype has not been previously reported for miR-146b, retroviral over-expression of miR-146a in T cells was shown to impair TCR-mediated proliferation. Conversely, mir-146adeficiency promotes hyperproliferation of T cells in response to antigen. 20 Hence, there is likely a threshold of miR-146 activity necessary to disrupt normal T cell function. Nevertheless, miR-146a and miR-146b extend tPTEN -/survival to a similar extent, which implies that in the context of tumor formation and growth, the more modest degree of miR-146a activity is sufficient to mediate its anti-tumor effects. Thus, increased miR-146 expression might slow expansion of malignant CD4 T cells or premalignant thymocytes in tPTEN -/mice. In further support of redundant function of these miRNAs, we also found that mir-146a-deficiency alone is not sufficient to accelerate lymphomagenesis in tPTEN -/mice (supplemental Figure 8 ).
Traf6 is a key activator of NF-κB downstream of TCR signaling. 22 Consistent with Traf6 being a primary target of miR-146 in thymocytes and T cells, miR-146 over-expression
For personal use only. on November 16, 2017. by guest www.bloodjournal.org From phenocopies aspects of NF-κB deficiency in T cells, which results in decreased T cell numbers and/or impaired TCR-mediated proliferation and survival. 25, [32] [33] [34] [35] [36] This defect was attributed to inhibition of NF-κB-dependent induction of c-myc, resulting in defective entry into S-phase. 25 Similarly, in mir-146b transgenic CD4 T cells, we observed reduced c-myc induction and delayed S-phase entry in response to TCR stimulation. Thus, attenuation of NF-κB signaling through targeting of Traf6 likely accounts for much of the mir-146b mature T cell phenotype.
More modest targeting of Traf6 by miR-146a and differential regulation of p27 levels likely accounts for the normal phenotype of mir-146a transgenic T cells.
Our data support a tumor suppressive role for miR-146a and miR-146b in murine T cell malignancies mediated by repression of TCR signaling and NF-κB activation. These observations are supported by recent analysis of mir-146a-deficient mice, which develop a multi-organ inflammatory disease starting at 6-8 months-of-age that culminates in the development of myeloid sarcomas and some B and T cell lymphomas. 37, 38 Consistent with miR-146 playing a tumor suppressive role in human myeloid malignancies, miR-146a was significantly downregulated in several studies profiling miRNA expression in acute and chronic myeloid leukemia (AML/CML) samples and myelodysplastic 5qsyndrome. [39] [40] [41] [42] [43] Also, enforced expression of miR-146a in AML cells lines inhibited cell proliferation and increased sensitivity to anti-leukemic drugs. 41 In support of a tumor suppressive role for miR-146 in human T cell malignancies, a comprehensive screen of miRNA expression in 50 primary T-ALL samples showed considerable downregulation of miR-146a expression in T-ALL samples compared to normal T cell controls. 44 Interestingly, studies have shown that NF-κB is often activated downstream of NOTCH1 in human T-ALL cell lines and treatment with the NF-κB inhibitor bortezomib significantly inhibits their growth. 45, 46 Hence, miR-146 based therapeutics that act to down-modulate NF-κB activity might be effective in treating T-ALL. In support of this notion and its potentially broader applicability, re-expression of miR-146a in cancer cell lines of nonhematopoietic tumor types in which NF-κB is hyperactivated, such as pancreatic and breast 
